Evidence map›Paper›PMID 37509288›Full record

ArticleCancers2023

Clinical Trial on the Safety and Tolerability of Personalized Cancer Vaccines Using Human Platelet Lysate-Induced Antigen-Presenting Cells.

Terutsugu Koya, Kenichi Yoshida, Misa Togi, Yo Niida, Sumihito Togi, Hiroki Ura, Shuichi Mizuta, Tomohisa Kato, Sohsuke Yamada, Takeo Shibata and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Terutsugu KoyaDepartment of Regenerative Medicine, Kanazawa Medical University, Kahoku 920-0293, Ishikawa, Japan.ORCID 0000-0003-0804-1045
Kenichi YoshidaCenter for Regenerative Medicine, Kanazawa Medical University Hospital, Kahoku 920-0293, Ishikawa, Japan.
Misa TogiDepartment of Regenerative Medicine, Kanazawa Medical University, Kahoku 920-0293, Ishikawa, Japan.ORCID 0000-0002-7424-4548
Yo NiidaDivision of Genomic Medicine, Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Kahoku 920-0293, Ishikawa, Japan.ORCID 0000-0001-5641-7962
Sumihito TogiDivision of Genomic Medicine, Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Kahoku 920-0293, Ishikawa, Japan.ORCID 0000-0002-3189-8111
Hiroki UraDivision of Genomic Medicine, Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Kahoku 920-0293, Ishikawa, Japan.ORCID 0000-0002-7600-3481
Shuichi MizutaDepartment of Hematology and Immunology, Kanazawa Medical University, Kahoku 920-0293, Ishikawa, Japan.
Tomohisa KatoDivision of Stem Cell Medicine, Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Kahoku 920-0293, Ishikawa, Japan.
Sohsuke YamadaDepartment of Pathology and Laboratory Medicine, Kanazawa Medical University, Kahoku 920-0293, Ishikawa, Japan.ORCID 0000-0003-2662-0024
Takeo ShibataDepartment of Obstetrics and Gynecology, Kanazawa Medical University, Kahoku 920-0293, Ishikawa, Japan.
Yi-Chang LiuDivision of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.
Shyng-Shiou YuanOffice of Research & Development, Kaohsiung Medical University, Kaohsiung 807, Taiwan.ORCID 0000-0002-4753-788X
Deng-Chyang WuInternal Medicine, School of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Hirohito KobayashiDivision of Transfusion and Cell Therapy, Tokyo Women's Medical University, Adachi Medical Center, Adachi 123-8558, Tokyo, Japan.
Taiju UtsugisawaDepartment of Transfusion Medicine and Cell Processing, Tokyo Women's Medical University, Shinjuku 162-8666, Tokyo, Japan.
Hitoshi KannoDepartment of Transfusion Medicine and Cell Processing, Tokyo Women's Medical University, Shinjuku 162-8666, Tokyo, Japan.
Shigetaka ShimodairaDepartment of Regenerative Medicine, Kanazawa Medical University, Kahoku 920-0293, Ishikawa, Japan.ORCID 0000-0002-6612-6912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research and development of personalized cancer vaccines as precision medicine are ongoing. We predicted human leukocyte antigen (HLA)-compatible cancer antigen candidate peptides based on patient-specific cancer genomic profiles and performed a Phase I clinical trial for the safety and tolerability of cancer vaccines with human platelet lysate-induced antigen-presenting cells (HPL-APCs) from peripheral monocytes. Among the five enrolled patients, two patients completed six doses per course (2-3 × 10

Indexed as

antigen-presenting cellsenzyme-linked immunosorbent assayin silico predictionmemory T cellspersonalized cancer vaccine

Identifiers

PMID37509288
PMCPMC10377585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.